Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 5/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | TNKS | O95271 | 3/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6047373 | 0.71 | MAOB (0.40) | ADORA2A | |
| SCHEMBL513059 | 0.69 | NR3C1 (0.42) | NR3C1HCAR2 | |
| SCHEMBL7629569 | 0.66 | CTRB1 (0.53) | — | |
| SCHEMBL2858795 | 0.65 | CTRB1 (0.52) | — | |
| SCHEMBL5501059 | 0.63 | CTRB1 (0.42) | — | |
| SCHEMBL4599933 | 0.62 | HDAC8 (0.41) | — | |
| SCHEMBL370376 | 0.62 | HCAR2 (0.52) | NR3C1HCAR2 | |
| SCHEMBL13223295 | 0.61 | CTRB1 (0.47) | ADORA2A | |
| SCHEMBL512164 | 0.61 | NR3C1 (0.46) | NR3C1HCAR2 | |
| SCHEMBL7322892 | 0.61 | HDAC8 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066413-B2 | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2021-07-20 | — | — | US | disclosed |
| US-20200048270-A1 | AMINOPYRIMIDINE FIVE-MEMBERED HETEROCYCLIC COMPOUND, AND INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048270-A1 | AMINOPYRIMIDINE FIVE-MEMBERED HETEROCYCLIC COMPOUND, AND INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ADORA2A, ADORA2B, ADORA3 | NR3C1 1006/4885SLC6A5 1901/4885TYMP 206/4885 |
| US-11066413-B2 | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof | ADORA2A, ADORA2B, ADORA3 | NR3C1 1006/4885SLC6A5 1901/4885TYMP 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.